Targeting an unexpected vulnerability p53-inactivated triple negative breast cancer
PROTAC, a new MDM2-targeted degrader, kills p53-inactivated triple negative breast cancer cells and suggests a new potential therapeutic target
Day: July 10, 2023
PROTAC, a new MDM2-targeted degrader, kills p53-inactivated triple negative breast cancer cells and suggests a new potential therapeutic target